Beijing Zimeng Pharmaceutical Technology

Zimeng Pharmaceutical is a clinical-stage biotechnology company based in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics for metabolic and chronic inflammatory diseases. The company's lead candidate, ZM-H1505, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Zimeng's pipeline also features promising programs targeting obesity and type 2 diabetes, including oral GLP-1 receptor agonists. By focusing on structure-based drug design, the company aims to create best-in-class or first-in-class treatments that address significant global health challenges. Zimeng has successfully secured multiple rounds of financing from prominent venture capital firms to accelerate its clinical programs.